ArticleJournal of managed care & specialty pharmacy2026
Herpes zoster vaccine uptake following provider prescription among older adults in the United States.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite broad recommendations in older adults, uptake for the 2-dose recombinant zoster vaccine (RZV), which protects against herpes zoster (ie, shingles), has historically been low in the United States among those aged 50 years and older. By recommending RZV, health care providers play a critical role in encouraging shingles prevention among older adults. A vaccine prescription may reinforce a recommendation, but understanding the extent and associated characteristics of uptake following prescription is needed.
objectiveTo describe RZV uptake following an RZV prescription among US adults aged 50 years and older.
methodsRZV uptake following a prescription among adults aged 50 years and older in the United States was assessed from 2017 to 2023 using administrative claims data linked with electronic health records. Patient demographic and clinical characteristics, provider characteristics, and health system factors were presented descriptively and compared between those with and without RZV administration following a prescription. A Cox proportional hazards model assessed associations between patient, provider, and health system factors and RZV administration following an RZV prescription.
resultsOf the 8,715 patients with an RZV prescription included, vaccine uptake following prescription was generally high: 71% of patients received at least 1 RZV dose following prescription, of which 82% were administered in a pharmacy setting. Among prescriptions with a known provider specialty source, 91% were written by primary care physicians or internal medicine providers. Factors such as Medicare Advantage with Part D coverage (vs commercial insurance), household income of at least $75,000 (vs <$40,000), and having an immunocompromising or autoimmune condition were associated with higher rates of RZV administration following a prescription.
conclusionsReceipt of RZV is likely following a healthcare provider's recommendation, as shown by the high uptake observed among adults who received RZV prescriptions in this study. Additional efforts are needed to ensure full adherence with provider recommendations for herpes zoster prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.